Noxxon Pharma
www.noxxonpharma.com
New class of therapeutics: Spiegelmers

Development of a new class of therapeutics: Spiegelmers (mirror image RNA aptamers), with potential to replace monoclonal antibodies. First products target inflammatory diseases and back-of-the-eye conditions. Validating partnerships with Pfizer, Roche & Lilly.

News :


NOXXON to initiate Phase Ib...
07/07/2010

NOXXON to initiate Phase Ib clinical trial of MCP-1 inhibitor NOX-E36
Read more
PDF File

Noxxon Pharma AG announces...
06/28/2010

Noxxon Pharma AG announces management changes
Read more
PDF File

Noxxon Pharma raises € 33m in...
05/27/2010

Noxxon Pharma raises € 33m in a Series D round of financing in which Seventure took part
Read more
PDF File

NOXXON Announces the...
05/04/2010

NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer NOX-A12
Read more
PDF File

Noxxon Pharma AG Achieves...
12/03/2009

Noxxon Pharma AG Achieves Milestone in Partnership with Eli Lilly and Company
Read more
PDF File

NOXXON Pharma AG announces...
10/14/2009

...
Read more
PDF File

NOXXON Announces Initiation...
06/08/2009

NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer
Read more
PDF File

Noxxon Pharma announces...
07/08/2008

Noxxon Pharma announces appointment of Lawrence E. Posner to its Board of Directors
Read more
PDF File

NOXXON Pharma AG Announces...
06/12/2008

NOXXON Pharma AG Announces Licensing and Discovery Collaboration with Eli Lilly and Co.
Read more
PDF File

NOXXON announces alliance...
11/09/2007

NOXXON announces alliance with Roche
Read more
PDF File